



THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Chandler Fulton, et al.

Title:

THIAMINASES AND

THIAMINASE GENES FOR

USE IN APOPTOTIC

THERAPIES

Appl. No.:

09/675,509

Filing Date:

09/29/2000

Examiner:

T. Ton

Art Unit:

1632

CERTIFICATE OF MAILING
I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on the date below.

(Printed Name)

(Signature)

(Date of Deposit)

RECEIVED

JAN 0 9 2002

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACAD CENTER 1600/2900 SEQUENCE DISCLOSURES

Commissioner for Patents Washington, D.C. 20231

Sir:

Responsive to the Notice To Comply With Requirements For Patent Applications containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed July 20, 2001, attached hereto are the following to complete the formal filing requirements in the above-identified application:

- [X] Amendment (11 pgs.)
- [X] Drawings (6 sheets)
- [X] Copy of Notice to Comply With Requirements For Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures
- [X] Statement To Support Filing and Submission In Accordance With 37 CFR 1.821-1.825.
- [X] Sequence Lisiting
- [X] Computer Readable Disk containing Sequence Listing
- [X] Petition for Extension of Time (2 Months)



- [X] Change of Correspondence Address
- [X] A check in the amount of \$200.00 is enclosed.
- [] The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 C.F.R. §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 50-0872. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 50-0872.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date _ 19 Octube 2001

FOLEY & LARDNER P.O. Box 80278

San Diego, California 92138-0278

Telephone:

(858) 847-6714

Facsimile:

(858) 792-6773

Ву

Wesley B. Ames

Attorney for Applicant

Registration No. 40,893

Application No. 09/675,509

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.		
	2. This application does not contain, as a separate part of the disclosure on paper Listing" as required by 37 C.F.R. 1.821(c).	er copy, a "Sequence
	3. A copy of the "Sequence Listing" in computer readable form has not been sub 37 C.F.R. 1.821(e).	mitted as required by
	4. A copy of the "Sequence Listing" in computer readable form has been content of the computer readable form does not comply with the requirements and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence".	of 37 C.F.R. 1.822
	5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).	
П	6. The paper copy of the "Sequence Listing" is not the same as the computer read "Sequence Listing" as required by 37 C.F.R. 1.821(e).	adable from of the
		RECEIVED
	7. Other:	JAN 0 9 2002
Applicant Must Provide:		TECH CENTER 1600/2900
X	An <u>initial</u> or substitute computer readable form (CRF) copy of the "Sequence List	ting".
X	An <u>initial</u> or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.	
X	A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).	
For questions regarding compliance to these requirements, please contact:		
For Rules Interpretation, call (703) 308-4216		
For CRF Submission Help, call (703) 308-4212		
PatentIn Software Program Support (SIRA) Technical Assistance		
	To Purchase Patentin Software703-306-2600	

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE